Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
September 24, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
Belships ASA: Key information relating to the cash dividend to be paid by Belships ASA
September 24, 2024 01:01 ET
|
Belships ASA
Oslo, 24 September 2024 The distribution will be made as an ordinary dividend Dividend amount: NOK 1.00 per share Declared currency: NOK Last day including right: 25 September 2024 Ex date: 26...
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024 01:00 ET
|
Biogen Inc.
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...
Nature Reviews Highlights Significant Successes of Antibiotic Collaboration and Calls for Sustainable R&D Funding Schemes
September 24, 2024 01:00 ET
|
BioVersys
BASEL, Switzerland, Sept. 24, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for...
EfTEN REAL ESTATE FUND AS NOTICE CALLING THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
September 24, 2024 01:00 ET
|
EfTEN Real Estate Fund AS
The Management Board of EfTEN Real Estate Fund AS (registry code 12864036; seat Tallinn, A. Lauteri 5) calls the extraordinary general meeting of shareholders on 16 October 2024 at 15:00. ...
Start of Day Message
September 24, 2024 01:00 ET
|
GlobeNewswire, Inc.
LONDON, 24 Sep. 2024 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information...
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
September 24, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing...
Belships ASA: Extraordinary dividend payment
September 24, 2024 01:00 ET
|
Belships ASA
Oslo, 24 September 2024 The sale of the debt-free supramax vessels BELFRIEND and BELTIDE has been completed and the sale proceeds of USD 56.6m have been received. Due to the Company's strong...
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
September 24, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers...
ABC arbitrage: HY 2024 Results
September 24, 2024 01:00 ET
|
ABC arbitrage
Press release - Paris, Septembre 24, 2024 - 07:00am HY 2024 Results¹: €8.9 mAnnualised ROE 2024: 11.2% | Minimal per share distribution 2024: €0.30 The Board of Directors of ABC arbitrage, presided...